ANTH - Anthera Pharmaceuticals, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Small med firms see increased buying
• Anthera Pharma to be delisted tomorrow; shares down 33.5%
• Premarket Losers as of 9:05 am (3/12/2018)
• Anthera to terminate development of Sollpura after failed late-stage study
• Key events next week - healthcare
• Anthera Pharma registers $100M mixed shelf offering
• Anthera Pharmaceuticals misses by $0.07
• Midday Gainers / Losers (2/21/2018)
• Anthera up big ahead of late-stage data readout for Sollpura, shares ahead 54%
• Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/21/2018)
• Premarket analyst action - healthcare
• Key healthcare events next week (continued)
• Anthera on go to report results from late-stage study of Sollpura in EPI this quarter; shares ahead 3%
• Planned equity offering roundup - healthcare
• Anthera continues up move after completing enrollment in late-stage Sollpura study; shares ahead 9%
• Anthera Pharma net loss improves in Q3
• Anthera Pharmaceuticals reports Q3 results
• Anthera prices private stock offering at $1.25; shares down 10%
• Anthera's blisibimod shows long-term treatment benefit in mid-stage study in IgA nephropathy; shares ahead 12% premarket
• Anthera's late-stage study of Sollpura to be included in European CF network; shares ahead 9% premarket